ARCHIVES

ODAC Reviews Post-Marketing Studies for Eight Indications

This article is from The Cancer Letter archive.

Vol. 29 No. 12 | March 21, 2003

Download PDF Visit The Full Archive

Related Articles

Endostatin Enters Phase II Trial For Neuroendocrine Tumors.

December 14, 2001

UCSD Center Designated Comprehensive; Siteman Center In St. Louis Wins Core Grant.

August 31, 2001

Cooperative Group Chairman Unhappy Over Exclusion From Funding at Recommended Levels

December 2, 1983

Wynder’s Low Fat Adjuvant Breast Cancer Study Finally Funded

October 21, 1988

NCCR Calls For 15% Increase In NIH Budget, “Investment Priority”

February 11, 1994

Editorial: Rumor Mill Fills The Gap When Access Denied

December 16, 1994